Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
NASDAQ:LGND 12:16:12 PM EDT
| Market Cap (Intraday) | 2.39B |
| Current PE | N/A |
| Forward PE | 23.27 |
| 2yr Forward PE | 29.18 |
| 10-Day MA | $150.52 |
| 50-Day MA | $159.34 |
| 200-Day MA | $118.22 |
Ligand Pharmaceuticals, Inc. Stock, NASDAQ:LGND
3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121
United States of America
Phone: +1.858.550.7500
Number of Employees: 115
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.